Table 1. Plasma Pharmacokinetic Parameters of Complement C5a Receptor 1 Antagonistsa.
PMX53 | PMX205 | ||||||||
---|---|---|---|---|---|---|---|---|---|
parameters | units | i.v. | s.c. | i.p. | p.o. | i.v. | s.c. | i.p. | p.o. |
Cmax | μg/mL | 17.42 | 3.77 | 4.92 | 0.25 | 34.62 | 5.62 | 5.95 | 0.77 |
Tmax | min | 27.22 | 14.28 | 21.91 | 27.98 | 14.28 | 27.72 | ||
Vss | mL | 2.90 | 2.76 | ||||||
V1_F | mL | 1.72 | <0.01 | <0.01 | 0.05 | 0.87 | <0.01 | <0.01 | 0.01 |
CL_F | μL/min | 199.16 | 0.11 | 0.16 | 2.01 | 146.90 | 0.07 | 0.13 | 0.52 |
V2_F | mL | 1.05 | <0.01 | <0.01 | <0.01 | 2.04 | <0.01 | <0.01 | <0.01 |
CLD2_F | μL/min | 84.57 | <0.01 | <0.01 | <0.01 | 197.45 | <0.01 | <0.01 | <0.01 |
K01 | 1/h | 2.28 | 4.29 | 2.92 | 2.21 | 4.30 | 2.24 | ||
K10 | 1/h | 6.94 | 2.13 | 4.11 | 2.56 | 10.17 | 2.08 | 4.10 | 2.09 |
K12 | 1/h | 2.95 | <0.001 | <0.001 | <0.001 | 13.67 | <0.001 | <0.001 | <0.001 |
K21 | 1/h | 4.85 | 2.14 | 2.00 | 2.58 | 5.82 | 2.08 | 2.00 | 2.09 |
K01_HL | min | 18.28 | 9.70 | 14.23 | 18.85 | 9.67 | 18.55 | ||
K10_HL | min | 5.99 | 19.47 | 10.10 | 16.22 | 4.09 | 19.93 | 10.13 | 19.85 |
Alpha | 1/min | 0.20 | 0.04 | 0.07 | 0.04 | 0.46 | 0.03 | 0.07 | 0.03 |
Beta | 1/min | 0.05 | 0.04 | 0.03 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 |
Alpha_HL | min | 3.49 | 19.53 | 10.11 | 16.32 | 1.51 | 20.00 | 10.14 | 19.92 |
Beta_HL | min | 14.73 | 19.42 | 20.75 | 16.02 | 19.33 | 19.92 | 20.75 | 19.87 |
MRT_last | min | 13.21 | 38.77 | 27.43 | 32.61 | 19.74 | 40.71 | 24.78 | 37.68 |
MRT_INF_obs | min | 18.03 | 47.94 | 36.15 | 33.97 | 37.00 | 64.30 | 26.30 | 54.41 |
MRT_INF_pred | min | 17.92 | 48.13 | 36.08 | 34.07 | 37.29 | 64.29 | 26.34 | 54.19 |
Cmax: peak plasma drug concentration; Tmax: time to reach peak plasma concentration following drug administration; Vss: apparent volume of distribution at a steady state; V1_F and V2_F: apparent volume of central and peripheral compartments in two compartmental models; CL_F and CLD2_F: apparent total body clearance of the drug from plasma and apparent total clearance of the drug from plasma after administration; K01: absorption rate constant; K10: elimination rate constant; K12 and K21: distribution and redistribution rate constant; K01_HL and K10_HL: distribution half-life and elimination half-life; Alpha and Beta: hybrid first-order rate constants expressing initial and terminal slopes of distribution and elimination phases; Alpha_HL and Beta_HL: initial or disposition half-life and terminal elimination half-life; MRT_last, MRT_INF_obs, and MRT_INF-pred: mean residence time at the last time point, infinity observed, and infinity predicted using two-compartmental analysis.